Abstract:Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, conferring durable and sometimes curative responses in patients with advanced-stage disease. The CAR T cell products currently approved for clinical use are all autologous and are often effective; however, in patients who are lymphopenic and/or heavily pretreated with chemotherapy, autologous T cells can be difficult to harvest in sufficient numbers or have functional impairments that might ultimately render them less efficacious. Moreover, autologous products take several weeks to produce, and each product can be used in only one patient. By contrast, allogeneic CAR T cells can be produced for many patients using T cells from a single healthy donor, can be optimized for safety and efficacy, can be instantly available for 'off-the-shelf' use and, therefore, might also be more cost-effective. Despite these potential advantages, the development of allogeneic CAR T cells has lagged behind that of autologous products, owing to the additional challenges such as avoiding graft-versus-host disease and host-mediated graft rejection. Over the past few years, the development of advanced genome-editing techniques has facilitated the generation of novel allogeneic CAR T cell products. Furthermore, CAR cell products derived from other cell types such as induced pluripotent stem cells and natural killer cells are being investigated for clinical use. In this Review, we discuss the potential of allogeneic CAR cell products to expand life-saving immunotherapy to a much broader population of patients in the coming years, the progress made to date and strategies to overcome remaining hurdles.

Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting

Overcoming the challenges encountered in CAR-T therapy: latest updates from the 2023 ASH annual conference

Toward “off‐the‐shelf” allogeneic CAR T cells

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Current state of CAR-T therapy for T-cell malignancies

Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Challenges and solutions to superior chimeric antigen receptor‐T design and deployment for B‐cell lymphomas

[Current state and future prospects of off-the-shelf allogeneic CAR NK therapy]

Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting

Advances in CAR-T-cell therapy in T-cell malignancies

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Allogeneic CAR-T cells for cancer immunotherapy

Recent updates on allogeneic CAR-T cells in hematological malignancies

Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Novel Cellular Immunotherapies for Hematological Malignancies: Recent Updates from the 2021 ASH Annual Meeting